Symmetry Partners LLC Invests $278,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Symmetry Partners LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,144 shares of the biopharmaceutical company’s stock, valued at approximately $278,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 2,517.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 4,809 shares during the period. Westpac Banking Corp grew its holdings in shares of Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 566 shares in the last quarter. Finally, Plato Investment Management Ltd increased its holdings in shares of Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 4,346 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.3 %

Shares of ALNY stock traded down $0.94 on Friday, reaching $269.52. The company’s stock had a trading volume of 529,266 shares, compared to its average volume of 898,002. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $274.93. The stock’s 50 day simple moving average is $220.68 and its 200-day simple moving average is $177.41. The company has a market capitalization of $34.09 billion, a P/E ratio of -100.57 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% compared to the same quarter last year. During the same quarter last year, the business posted ($2.21) EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Royal Bank of Canada boosted their price target on Alnylam Pharmaceuticals from $265.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research report on Wednesday, July 3rd. Evercore ISI increased their price target on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. Cantor Fitzgerald boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Eight analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $269.32.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Insiders have sold 109,848 shares of company stock valued at $24,683,444 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.